Global Stock News

Amgen Stock Analysis: Repatha Surges 34% But Tax Litigation Clouds the Return Case. Here’s What to Expect

Amgen Stock Analysis: Repatha Surges 34% But Tax Litigation Clouds the Return Case. Here’s What to Expect

Key Stats for Amgen Stock

  • 52-Week Range: $268 to $391
  • Current Price: $326
  • Street Mean Target: $352
  • Street High Target: $427
  • Analyst Consensus: 10 Buys / 4 Outperforms / 18 Holds / 1 Underperform / 2 Sells
  • TIKR Model Target (Dec. 2030): $462

Most investors never know if a stock is truly undervalued or overpriced. TIKR’s professional-grade valuation tools give you a clear, data-backed answer across 60,000+ stocks for free →

Amgen Beats Q1 Estimates but Tavneos Fallout and a $10.7 Billion IRS Cloud Keep Investors on Edge

Amgen Inc. (AMGN) is one of the world’s largest biotechnology companies, generating over $37 billion in annual revenue by selling treatments for cardiovascular disease, rare autoimmune…

Source link

Share this article

Scroll to Top